We draw upon the expertise of our strategic partners to continually enhance the value of our products and services. If you are interested in becoming a Golden Helix® partner, please contact us.
Golden Helix is an Affymetrix GeneChip-compatible software provider and is committed to seamlessly integrating SNP & Variation Suite with Affymetrix technology. Since developing the world's first microarray in 1989, Affymetrix GeneChip technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 3,000 peer-reviewed papers have been published using the technology.
For more information about Affymetrix, visit www.affymetrix.com.
Golden Helix is a founding partner in Complete Genomics' Genomic Discovery Software Partners Program.
The Genomic Discovery Software Partners Program was developed in 2012 to give the entire genetic research community access to solutions compatible with Complete Genomics' data to accelerate the pace of biological discoveries. Whereas Complete Genomics technology excels at mapping, genome assembly, and variant calling of sequence data, SNP & Variation Suite provides complementary analytics in a desktop solution that combines powerful variant classification, bioinformatic filtering, functional annotation, visualization, and statistical analysis capabilities.
For more information about Complete Genomics, visit www.completegenomics.com.
Golden Helix and Expression Analysis have created an end-to-end analysis solution for RNA-Seq data. This sophisticated yet user-friendly offering addresses the obstacles of next-gen sequencing analytics by providing a collection of tightly coupled cloud-based and desktop analysis tools that are scalable, affordable, and comprehensive. Primary and secondary analyses are delivered through the cloud, where data is stored and managed with an easy-to-use interface. When users are ready to "make sense" of this data (tertiary analysis), Golden Helix provides differential expression workflows optimized for RNA-Seq data in its SNP & Variation Suite. The third component of the solution is a powerful, multi-sample genome browser optimized for streaming data directly from the cloud.
For more information about Expression Analysis, visit www.expressionanalysis.com.
GlaxoSmithKline (GSK), the world's second largest pharmaceutical company, and Golden Helix have collaborated to jointly develop functionality within Golden Helix software setting the industry standard in genetics analysis. GSK is an early investor of Golden Helix and has licensed two of its recursive partitioning software patents to GHI. GlaxoSmithKline continues to provide ongoing input of their world-class statistical geneticists and clinical trials statisticians in addition to having a non-exclusive world-wide site license.
For more information about GlaxoSmithKline, visit www.gsk.com.
Harvard University School of Public Health
Golden Helix and Christoph Lange, Ph.D. of the Harvard School of Public Health, have joined together to provide the genetic research community with a commercial edition of the PBAT software, offering tools for family-based genetic association studies. Dr. Lange has been involved in the field of statistical genetics since he finished his Ph.D. studies at the Department of Applied Statistics, University of Reading, UK in 2000. He currently is Assistant Professor of Biostatistics at the Harvard School of Public Health.
For more information about the Harvard School of Public Health, visit www.hsph.harvard.edu.
Golden Helix is a charter member of the Illumina Connect Program, a bioinformatics software partnership program established by Illumina to advance data integration and analysis. In collaboration with Illumina, Golden Helix has developed a BeadStudio plug-in that enables researchers to export genotype data in an exceedingly compact storage format. This format enables efficient sharing and analysis by users of Golden Helix SNP & Variation Suite, and also streamlines the transfer, management, and downstream analysis of large-scale genetic data.
For more information about Illumina, visit www.illumina.com.
Golden Helix is a member of the Pacific Biosciences Partner Program, which provides end-to-end solutions for de novo whole genome assembly and targeted sequencing.
The Pacific Biosciences Partner Program was developed to identify solutions that complement and enhance key aspects of the PacBio RS sequencing workflow, providing customers with integrated workflows from sample preparation to analysis. On the informatics side, SNP & Variation Suite provides an integrated collection of user-friendly, yet powerful tools for variant classification, bioinformatic filtering, functional annotation, visualization, and statistical analysis for quickly uncovering statistically significant genotype/phenotype associations or causal variants from PacBio variant calls.
For more information about Pacific Biosciences, visit www.pacificbiosciences.com.
Filgen is distributor of Golden Helix software in Japan.
Filgen Inc. engages in the development, manufacturing, and sales of science research equipment and provides biotechnology analysis services to the life sciences market. The company offers nano-science products, such as ultraviolet radiation ozone cleaner, spectrum osmium, dipping device, plasma film manufacture device, simple dipping device, and electron microscope trust photographing service. Filgen Inc. was founded in 2004 and is based in Nagoya, Japan.
For more information about Filgen, visit www.filgen.jp.
GeneGo is a leading provider of data mining & analysis solutions and is a distributor of ChemTree through integration with GeneGo's MetaDrug product. MetaDrug is GeneGo's fully assembled systems pharmacology platform that can be used to predict human metabolites, toxicity and mode of action of novel small molecule compounds. In addition to MetaDrug, GeneGo provide systems biology solutions for a full range of applications in life science research and drug development, from pre-clinical discovery and NCE applications to clinical trials, covering all aspects of biology and chemistry.
For more information about GeneGo, visit www.genego.com.